A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD)

References

• ArmstrongDTalleyNJLauritsenKThe role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazoleAliment Pharmacol Ther2004204132115298635
   PubMed Web of Science ®Google Scholar
• BellNJBurgetDHowdenAppropriate acid suppression for the management of gastro-oesophageal reflux diseaseDigestion199251Suppl 159671397746
   PubMed Web of Science ®Google Scholar
• BjornssonEAbrahamssonHSimrenMDiscontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trialAliment Pharmacol Ther2006249455416948806
   PubMed Web of Science ®Google Scholar
• CastellDOKahrilasPJRichterJEEsomeprazole 40 mg. compared with lansoprazole 30 mg. in the treatment of erosive esophagitisAm J Gastroenterol2002975758311922549
   PubMed Web of Science ®Google Scholar
• DelaneyBMcCollKReview article: Helicobacter pylori and gastro-oesophageal reflux diseaseAliment Pharmacol Ther200522Suppl 1324016042657
   PubMed Web of Science ®Google Scholar
• DentJEl-SeragHBWallanderMAEpidemiology of gastro-oesophageal reflux disease: a systematic reviewGut2005547101715831922
   PubMed Web of Science ®Google Scholar
• DeVaultKRCastellDOUpdated guidelines for the diagnosis and treatment of gastroesophageal reflux diseaseAm J Gastroenterol200510019020015654800
   PubMed Web of Science ®Google Scholar
• DevaultKRJohansonJFJohnsonDAMaintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligramsClin Gastroenterol Hepatol20064852916682260
   PubMed Web of Science ®Google Scholar
• EdwardsSJLindTLundellLSystematic review of proton pump inhibitors for the acute treatment of reflux oesophagitisAliment Pharmacol Ther20011517293611683686
   PubMed Web of Science ®Google Scholar
• EdwardsSJLindTLundellLSystematic review: proton pump inhibitors PPIs. for the healing of reflux oesophagitis – a comparison of esomeprazole with other PPIsAliment Pharmacol Ther2006247435016918878
   PubMed Web of Science ®Google Scholar
• FennertyMBJohansonJFHwangCEfficacy of esomeprazole 40 mg vs lansoprazole 30 mg for healing moderate to severe erosive oesophagitisAliment Pharmacol Ther2005214556315709997
   PubMed Web of Science ®Google Scholar
• FockKMTeoEKAngTLRabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban AsiaWorld J Gastroenterol2005113091815918196
   PubMed Web of Science ®Google Scholar
• FrazzoniMDe MicheliESavarinoVDifferent patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux diseaseAliment Pharmacol Ther2003181091814653828
   PubMed Web of Science ®Google Scholar
• FrazzoniMMannoMDe MicheliEIntra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazoleDig Liver Dis200638859016289976
   PubMedGoogle Scholar
• GillessenABeilWModlinIM40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptomsJ Clin Gastroenterol2004383324015087692
   PubMed Web of Science ®Google Scholar
• GralnekIMDulaiGSFennertyMBEsomeprazole Versus Other Proton Pump Inhibitors in Erosive Esophagitis: A Meta-Analysis of Randomized Clinical TrialsClin Gastroenterol Hepatol200641452817162239
   PubMed Web of Science ®Google Scholar
• HansenANBergheimRFagertunHLong-term management of patients with symptoms of gastro-oesophageal reflux disease – a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners settingInt J Clin Pract200660152216409423
   PubMed Web of Science ®Google Scholar
• HatlebakkJGReview article: gastric acidity – comparison of esomeprazole with other proton pump inhibitorsAliment Pharmacol Ther200317Suppl 11015 discussion 16–1712614300
   PubMed Web of Science ®Google Scholar
• HellstromPMVitolsSThe choice of proton pump inhibitor: does it matter?Basic Clin Pharmacol Toxicol2004941061115049339
   PubMed Web of Science ®Google Scholar
• HoltmannGCainCMalfertheinerPGastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazoleGastroenterology1999117111610381904
   PubMed Web of Science ®Google Scholar
• HowdenCWBallardEDIIRobiesonWEvidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole in the treatment of erosive esophagitisClin Drug Investig20022299109
   PubMed Web of Science ®Google Scholar
• HuntRHImportance of pH control in the management of GERDArch Intern Med19991596495710218743
   PubMed Web of Science ®Google Scholar
• JohanssonKEAskPBoerydBOesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux diseaseScand J Gastroenterol198621837473775250
   PubMed Web of Science ®Google Scholar
• JohnsonDABenjaminSBVakilNBEsomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safetyAm J Gastroenterol200196273411197282
   PubMed Web of Science ®Google Scholar
• JohnsonDAStacyTRyanMA comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux diseaseAliment Pharmacol Ther2005221293416011671
   PubMed Web of Science ®Google Scholar
• JohnssonFJoelssonBGudmundssonKSymptoms and endoscopic findings in the diagnosis of gastroesophageal reflux diseaseScand J Gastroenterol198722714183659834
   PubMed Web of Science ®Google Scholar
• KahrilasPJFalkGWJohnsonDAEsomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study InvestigatorsAliment Pharmacol Ther20001412495811012468
   PubMed Web of Science ®Google Scholar
• KatzPOCastellDOChenYIntragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover studyAliment Pharmacol Ther20042039940615298633
   PubMed Web of Science ®Google Scholar
• KendallMJReview article: Esomeprazole – the first proton pump inhibitor to be developed as an isomerAliment Pharmacol Ther200317Suppl 11412614298
   PubMed Web of Science ®Google Scholar
• KlokRMPostmaMJvan HoutBAMeta-analysis: comparing the efficacy of proton pump inhibitors in short-term useAliment Pharmacol Ther20031712374512755837
   PubMed Web of Science ®Google Scholar
• KuipersEJNelisGFKlinkenberg-KnolECCure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trialGut200453122014684569
   PubMed Web of Science ®Google Scholar
• KuligMLeodolterAViethMQuality of life in relation to symptoms in patients with gastro-oesophageal reflux disease – an analysis based on the ProGERD initiativeAliment Pharmacol Ther2003187677614535869
   PubMed Web of Science ®Google Scholar
• LabenzJArmstrongDLauritsenKEsomeprazole 20 mg vs pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO studyAliment Pharmacol Ther2005a228031116225489
   PubMed Web of Science ®Google Scholar
• LabenzJArmstrongDLauritsenKA randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO studyAliment Pharmacol Ther2005b217394615771760
   PubMed Web of Science ®Google Scholar
• LabenzJTillenburgBPeitzUHelicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcerGastroenterology1996110725328608881
   PubMed Web of Science ®Google Scholar
• LauritsenKDeviereJBigardMAEsomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study resultsAliment Pharmacol Ther2003173334112562445
   PubMed Web of Science ®Google Scholar
• LindTHavelundTCarlssonRHeartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic responseScand J Gastroenterol19973297499361168
   PubMed Web of Science ®Google Scholar
• LindTRydbergLKylebackAEsomeprazole provides improved acid control vs omeprazole In patients with symptoms of gastro-oesophageal reflux diseaseAliment Pharmacol Ther200014861710886041
   PubMed Web of Science ®Google Scholar
• MartinezSDMalagonIBGarewalHSNon-erosive reflux disease NERD – acid reflux and symptom patternsAliment Pharmacol Ther2003175374512622762
   PubMed Web of Science ®Google Scholar
• MiehlkeSMadischAKirschCIntragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two-way crossover studyAliment Pharmacol Ther200521963715813831
   PubMed Web of Science ®Google Scholar
• MinerPJrKatzPOChenYGastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover studyAm J Gastroenterol20039826162014687806
   PubMed Web of Science ®Google Scholar
• MoayyediPTalleyNJGastro-oesophageal reflux diseaseLancet2006367208610016798392
   PubMed Web of Science ®Google Scholar
• MonnikesHPfaffenbergerBGatzGNovel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazoleDigestion200571152815870503
   PubMed Web of Science ®Google Scholar
• PaceFNegriniCWiklundIQuality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux diseaseAliment Pharmacol Ther2005223495616098002
   PubMed Web of Science ®Google Scholar
• PrasadMRentzAMRevickiDAThe impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature reviewPharmacoeconomics2003217699012859219
   PubMed Web of Science ®Google Scholar
• RevickiDAWoodMMatonPNThe impact of gastroesophageal reflux disease on health-related quality of lifeAm J Med199810425289552088
   PubMed Web of Science ®Google Scholar
• RichterJEKahrilasPJJohansonJEfficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trialAm J Gastroenterol2001966566511280530
   PubMed Web of Science ®Google Scholar
• RohssKHasselgrenGHedenstromHEffect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux diseaseDig Dis Sci200247954812018920
   PubMed Web of Science ®Google Scholar
• RohssKLindTWilder-SmithCEsomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptomsEur J Clin Pharmacol200460531915349707
   PubMed Web of Science ®Google Scholar
• SchmittCLightdaleCJHwangCA multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole 40 mg, and omeprazole 20 mg. for the treatment of erosive esophagitisDig Dis Sci2006518445016642422
   PubMed Web of Science ®Google Scholar
• ScholtenTGatzGHoleUOnce-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptomsAliment Pharmacol Ther2003185879412969085
   PubMed Web of Science ®Google Scholar
• SimonBMullerPPascuOIntra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux diseaseEur J Gastroenterol Hepatol200315791912811310
   PubMed Web of Science ®Google Scholar
• TalleyNJLauritsenKTunturi-HihnalaHEsomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of on-demand therapy for 6 monthsAliment Pharmacol Ther2001153475411207509
   PubMed Web of Science ®Google Scholar
• TalleyNJVenablesTLGreenJREsomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 monthsEur J Gastroenterol Hepatol2002148576312172406
   PubMed Web of Science ®Google Scholar
• TsaiHHChapmanRShepherdAEsomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND StudyAliment Pharmacol Ther2004206576515352914
   PubMed Web of Science ®Google Scholar
• VakilNFennertyMBDirect comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer diseaseAliment Pharmacol Ther2003185596812969082
   PubMed Web of Science ®Google Scholar
• VakilNBShakerRJohnsonDAThe new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safetyAliment Pharmacol Ther2001159273511421866
   PubMed Web of Science ®Google Scholar
• VakilNvan ZantenSVKahrilasPThe Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensusAm J Gastroenterol2006101190020 quiz 194316928254
   PubMed Web of Science ®Google Scholar
• VerduEFArmstrongDFraserREffect of Helicobacter pylori status on intragastric pH during treatment with omeprazoleGut199536539437737560
   PubMed Web of Science ®Google Scholar
• Wilder-SmithCHRohssKNilsson-PieschlCEsomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteersDigestion200368184814691345
   PubMed Web of Science ®Google Scholar
• WuJCChanFKChingJYEffect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trialGut200453174914724146
   PubMed Web of Science ®Google Scholar